Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;45(3):261-266.
doi: 10.15537/smj.2024.45.3.20230840.

Outcomes of etonogestrel subdermal contraceptive implants: A single center cross-sectional study

Taghreed M Shams  1   2 , Hashem H Alhashemi  2 , Albaraa A Fallatah  2 , Asma M Alkhalid  2 , Fai M Alhazmi  2 , Mohammed K Bin Yunus  2 , Rani N Radey  2 , Asalah F Hamad  2 , Hatoon T Beyari  2 , Shahad S Alharazi  2
Affiliations

Outcomes of etonogestrel subdermal contraceptive implants: A single center cross-sectional study

Taghreed M Shams et al. Saudi Med J. 2024 Mar.

Abstract

Objectives: To examine the prevalence of menstrual irregularities, side effects, and discontinuation rates of etonogestrel subdermal implants (ESI) in women attending King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Methods: This cross-sectional was carried out based on electronic medical records and a phone-based questionnaire administered to women who underwent ESI insertion in a single tertiary care hospital in Jeddah, Saudi Arabia, between 2019 and 2022. The primary objective was the prevalence of menstrual abnormalities. The secondary study objective included the discontinuation rate, reasons for discontinuation, and ESI side effects.

Results: In total, 345 women with ESI were included in this study. The prevalence of any type of menstrual abnormalities was 88%. Other side effects included skin and mood changes, arm pain, and numbness. The discontinuation rate was 11% in the first year and 22% before the completion of 36 months.

Conclusion: Although menstrual abnormalities are a common side effect of ESI, only 22% of users discontinued this method of contraception.

Keywords: contraception; etonogestrel; implants; menstrual abnormalities.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Organon N. V.. NEXPLANON® and IMPLANON® (etonogestrel implant). [Updated 2011; accessed date?]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021529s011lbl.pdf
    1. Maddox DD, Rahman Z. Etonogestrel (Implanon), another treatment option for contraception. P T 2008. Jun;33: 337-347.
    1. Moray KV, Chaurasia H, Sachin O, Joshi B.. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health 2021; 18: 4. - PMC - PubMed
    1. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S.. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod 2015; 30: 2527-2538. - PubMed
    1. Aisien AO, Safety Enosolease ME., efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract 2010; 13: 331-335. - PubMed